Trial Profile
A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs NT 501 (Primary)
- Indications Retinal telangiectasis
- Focus Therapeutic Use
- Sponsors Neurotech USA
- 16 Jan 2019 According to a Neurotech Pharmaceuticals media release, results from this study were published in the journal of the American Academy of Ophthalmology, Ophthalmology.
- 16 Jan 2019 Results presented in a Neurotech Pharmaceuticals media release.
- 26 Jun 2017 Status changed from active, no longer recruiting to completed.